CompletedPhase 2NCT00611325

Phase II Avastin + Bortezomib for Patients With Recurrent Malignant Glioma

Studying Gliosarcoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Duke University
Principal Investigator
Katherine B Peters, MD, MD
Duke Health
Intervention
Avastin(drug)
Enrollment
56 enrolled
Eligibility
18 years · All sexes
Timeline
20082013

Study locations (1)

Collaborators

Millennium Pharmaceuticals, Inc. · Genentech, Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00611325 on ClinicalTrials.gov

Other trials for Gliosarcoma

Additional recruiting or active studies for the same condition.

See all trials for Gliosarcoma

← Back to all trials